Discussion
Recruitment is now underway in a new Phase 3 clinical trial testing SD-101, an experimental cream designed to promote wound healing in people with epidermolysis bullosa (EB). The Phase 3 SD-007 study (NCT07482787) is open to children, ages four weeks through 12 years, who have EB simplex,…